Log in

NYSE:ICLICL Group Competitors & Alternatives

$3.03
-0.08 (-2.57 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.00
Now: $3.03
$3.13
50-Day Range
$2.94
MA: $3.33
$3.70
52-Week Range
$2.68
Now: $3.03
$5.50
Volume205,700 shs
Average VolumeN/A
Market Capitalization$3.88 billion
P/E Ratio9.77
Dividend YieldN/A
BetaN/A

Competitors

ICL Group (NYSE:ICL) Vs. NTR, SMG, CF, MOS, AVD, and MBII

Should you be buying ICL stock or one of its competitors? Companies in the industry of "agricultural chemicals" are considered alternatives and competitors to ICL Group, including Nutrien (NTR), Scotts Miracle-Gro (SMG), CF Industries (CF), Mosaic (MOS), American Vanguard (AVD), and Marrone Bio Innovations (MBII).

ICL Group (NYSE:ICL) and Nutrien (NYSE:NTR) are both basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares ICL Group and Nutrien's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion0.74$475 million$0.378.19
Nutrien$20.02 billion0.90$992 million$2.1714.64

Nutrien has higher revenue and earnings than ICL Group. ICL Group is trading at a lower price-to-earnings ratio than Nutrien, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for ICL Group and Nutrien, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group01002.00
Nutrien161312.67

Nutrien has a consensus price target of $49.30, indicating a potential upside of 55.23%. Given Nutrien's stronger consensus rating and higher possible upside, analysts clearly believe Nutrien is more favorable than ICL Group.

Insider and Institutional Ownership

4.6% of ICL Group shares are owned by institutional investors. Comparatively, 62.2% of Nutrien shares are owned by institutional investors. 3.1% of Nutrien shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares ICL Group and Nutrien's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group7.65%9.60%4.20%
Nutrien4.49%4.66%2.27%

Summary

Nutrien beats ICL Group on 11 of the 14 factors compared between the two stocks.

Scotts Miracle-Gro (NYSE:SMG) and ICL Group (NYSE:ICL) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Valuation and Earnings

This table compares Scotts Miracle-Gro and ICL Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scotts Miracle-Gro$3.16 billion2.45$460.70 million$4.4731.11
ICL Group$5.27 billion0.74$475 million$0.378.19

ICL Group has higher revenue and earnings than Scotts Miracle-Gro. ICL Group is trading at a lower price-to-earnings ratio than Scotts Miracle-Gro, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Scotts Miracle-Gro and ICL Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Scotts Miracle-Gro9.49%42.92%8.99%
ICL Group7.65%9.60%4.20%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Scotts Miracle-Gro and ICL Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Scotts Miracle-Gro03302.50
ICL Group01002.00

Scotts Miracle-Gro presently has a consensus target price of $124.80, suggesting a potential downside of 10.26%. Given Scotts Miracle-Gro's stronger consensus rating and higher possible upside, research analysts plainly believe Scotts Miracle-Gro is more favorable than ICL Group.

Institutional & Insider Ownership

63.1% of Scotts Miracle-Gro shares are owned by institutional investors. Comparatively, 4.6% of ICL Group shares are owned by institutional investors. 28.2% of Scotts Miracle-Gro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Scotts Miracle-Gro beats ICL Group on 11 of the 13 factors compared between the two stocks.

CF Industries (NYSE:CF) and ICL Group (NYSE:ICL) are both basic materials companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares CF Industries and ICL Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CF Industries$4.59 billion1.31$493 million$1.9314.57
ICL Group$5.27 billion0.74$475 million$0.378.19

CF Industries has higher earnings, but lower revenue than ICL Group. ICL Group is trading at a lower price-to-earnings ratio than CF Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for CF Industries and ICL Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CF Industries29802.32
ICL Group01002.00

CF Industries currently has a consensus price target of $44.0588, suggesting a potential upside of 56.68%. Given CF Industries' stronger consensus rating and higher probable upside, analysts clearly believe CF Industries is more favorable than ICL Group.

Profitability

This table compares CF Industries and ICL Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CF Industries10.33%8.34%3.73%
ICL Group7.65%9.60%4.20%

Insider & Institutional Ownership

92.5% of CF Industries shares are owned by institutional investors. Comparatively, 4.6% of ICL Group shares are owned by institutional investors. 2.0% of CF Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

CF Industries beats ICL Group on 10 of the 13 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Mosaic (NYSE:MOS) are both basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares ICL Group and Mosaic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group7.65%9.60%4.20%
Mosaic-15.91%-0.53%-0.26%

Insider & Institutional Ownership

4.6% of ICL Group shares are held by institutional investors. Comparatively, 73.0% of Mosaic shares are held by institutional investors. 0.5% of Mosaic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ICL Group and Mosaic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group01002.00
Mosaic08802.50

Mosaic has a consensus price target of $17.00, suggesting a potential upside of 38.21%. Given Mosaic's stronger consensus rating and higher probable upside, analysts plainly believe Mosaic is more favorable than ICL Group.

Earnings & Valuation

This table compares ICL Group and Mosaic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion0.74$475 million$0.378.19
Mosaic$8.91 billion0.52$-1,067,400,000.00$0.1964.74

ICL Group has higher earnings, but lower revenue than Mosaic. ICL Group is trading at a lower price-to-earnings ratio than Mosaic, indicating that it is currently the more affordable of the two stocks.

Summary

ICL Group beats Mosaic on 7 of the 13 factors compared between the two stocks.

American Vanguard (NYSE:AVD) and ICL Group (NYSE:ICL) are both basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

79.6% of American Vanguard shares are owned by institutional investors. Comparatively, 4.6% of ICL Group shares are owned by institutional investors. 5.3% of American Vanguard shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for American Vanguard and ICL Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Vanguard00103.00
ICL Group01002.00

American Vanguard presently has a consensus target price of $19.00, suggesting a potential upside of 42.96%. Given American Vanguard's stronger consensus rating and higher possible upside, analysts clearly believe American Vanguard is more favorable than ICL Group.

Earnings and Valuation

This table compares American Vanguard and ICL Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Vanguard$468.19 million0.86$13.60 million$0.4628.89
ICL Group$5.27 billion0.74$475 million$0.378.19

ICL Group has higher revenue and earnings than American Vanguard. ICL Group is trading at a lower price-to-earnings ratio than American Vanguard, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares American Vanguard and ICL Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Vanguard2.20%3.03%1.52%
ICL Group7.65%9.60%4.20%

Summary

American Vanguard beats ICL Group on 8 of the 13 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Marrone Bio Innovations (NASDAQ:MBII) are both basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ICL Group and Marrone Bio Innovations' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion0.74$475 million$0.378.19
Marrone Bio Innovations$29.37 million5.35$-37,170,000.00($0.21)-5.14

ICL Group has higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than ICL Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ICL Group and Marrone Bio Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group7.65%9.60%4.20%
Marrone Bio Innovations-132.76%-136.82%-37.67%

Analyst Ratings

This is a breakdown of current recommendations and price targets for ICL Group and Marrone Bio Innovations, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group01002.00
Marrone Bio Innovations00303.00

Marrone Bio Innovations has a consensus target price of $1.8833, indicating a potential upside of 74.38%. Given Marrone Bio Innovations' stronger consensus rating and higher possible upside, analysts plainly believe Marrone Bio Innovations is more favorable than ICL Group.

Institutional and Insider Ownership

4.6% of ICL Group shares are owned by institutional investors. Comparatively, 35.0% of Marrone Bio Innovations shares are owned by institutional investors. 3.4% of Marrone Bio Innovations shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ICL Group beats Marrone Bio Innovations on 7 of the 13 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nutrien logo
NTR
Nutrien
2.4$31.76-1.6%$17.81 billion$20.02 billion20.23Decrease in Short Interest
Scotts Miracle-Gro logo
SMG
Scotts Miracle-Gro
1.8$139.07-1.0%$7.64 billion$3.16 billion24.36Insider Selling
CF Industries logo
CF
CF Industries
2.4$28.12-4.3%$5.75 billion$4.59 billion13.20Dividend Announcement
Heavy News Reporting
Mosaic logo
MOS
Mosaic
2.3$12.30-5.0%$4.43 billion$8.91 billion-3.34Analyst Upgrade
Heavy News Reporting
American Vanguard logo
AVD
American Vanguard
2.5$13.29-3.5%$386.64 million$468.19 million36.92
Marrone Bio Innovations logo
MBII
Marrone Bio Innovations
1.3$1.08-4.6%$157.17 million$29.37 million-3.27
Calyxt logo
CLXT
Calyxt
1.7$4.53-7.1%$149.67 million$7.30 million-3.43Decrease in Short Interest
Heavy News Reporting
CVR Partners logo
UAN
CVR Partners
1.3$0.82-4.9%$99.69 million$404.18 million-1.91
Arcadia Biosciences logo
RKDA
Arcadia Biosciences
1.3$3.72-0.3%$37.37 million$1.17 million-2.28
Evogene logo
EVGN
Evogene
0.6$1.00-2.0%$26.26 million$750,000.00-1.25
CGA
China Green Agriculture
0.8$2.84-3.5%$18.03 million$294.32 million0.00
SenesTech logo
SNES
SenesTech
0.6$2.04-4.9%$6.92 million$140,000.00-0.27
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.